Expand KURA Menu
KURA MENU

KURA Latest Press Releases

-- April 9, 2026 --

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 Globe Newswire 7:30 AM

-- April 3, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- March 6, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- March 5, 2026 --

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 6:31 AM

-- February 26, 2026 --

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 7:30 AM

-- February 25, 2026 --

Kura Oncology to Participate in Three Upcoming Investor Conferences Globe Newswire 7:30 AM

-- February 6, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- January 11, 2026 --

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones Globe Newswire 5:00 PM

-- January 5, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- December 8, 2025 --

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML Globe Newswire 10:30 AM

-- December 3, 2025 --

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Globe Newswire 8:32 AM

-- November 25, 2025 --

KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML) Globe Newswire 5:16 PM
Market Data Delayed 15 Minutes